Side-by-side comparison of AI visibility scores, market position, and capabilities
Dutch health technology company with €17B revenue; MRI/CT imaging and patient monitoring managing massive sleep apnea device recall competing with Siemens Healthineers and GE HealthCare.
Philips is a Dutch multinational technology and health technology company that has transformed from a broad consumer electronics conglomerate into a focused health technology leader — producing diagnostic imaging systems (MRI, CT, ultrasound), patient monitoring, hospital informatics, personal health products (electric toothbrushes, shavers, sleep apnea devices), and health informatics solutions. Listed on the Amsterdam Stock Exchange (AEX: PHIA) and headquartered in Amsterdam, Philips generates approximately €17 billion ($18 billion) in annual revenue after divesting its lighting division (now Signify) and domestic appliances business.\n\nPhilips' health technology portfolio spans two segments: Diagnosis & Treatment (imaging systems, image-guided therapy, and ultrasound for hospitals) and Connected Care (patient monitoring, respiratory care, sleep therapy). The Diagnosis & Treatment segment provides MRI systems, CT scanners, and X-ray equipment to hospitals globally. The Connected Care segment includes Philips' DreamStation and other sleep apnea (CPAP/BiPAP) devices, home respiratory care, and hospital patient monitoring platforms.\n\nIn 2025, Philips is managing the severe consequences of a 2021 recall of approximately 5.5 million sleep apnea devices (Philips Respironics DreamStation and related models) due to concerns that degraded polyester foam could release harmful particles and gases — one of the largest medical device recalls in history. The recall has resulted in multi-billion dollar settlements, regulatory scrutiny, and significant reputation damage in the sleep therapy market, allowing competitors ResMed and Fisher & Paykel to gain share. Philips' 2025 strategy focuses on resolving recall liabilities, rebuilding the sleep therapy business, and investing in AI-powered diagnostic imaging to compete with Siemens Healthineers and GE HealthCare.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.